SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Alnylam Pharmaceuticals Files Clinical Trial Application (CTA) for ALN-PCS, an RNAi Therapeutic Targeting PCSK9 for the Treatment of Severe Hypercholesterolemia